CR4 Human Colorectal Cancer Cell Line

• Each vial contains ≥1X10⁶ viable cells.
• Cells are tested negative for HPV-16, HPV-18, Hepatitis A, B, C, Herpesvirus type 7, 8 and HIV-1 & 2 viruses by PCR
• Cells are positive for herpesvirus type 6 by PCR analysis.
• Cells are negative for mycoplasma contamination.
• Each lot of cells is genotyped by STR analysis to verify the unique identity of the cell line.

RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.

CR4 is a novel CIC-enriched, highly tumorigenic, clonogenic and 3D spheroid-forming colon cancer cell line derived from the liver metastasis of a male patient with stage 4 colon cancer (1). Primary tumor cells were established on type I collagen coated flasks in serum-free stem cell media (1). Holoclones, small stem-like cells that are densely packed, were selectively subcloned from the heterogeneous culture and propagated. Cells were then passaged as 3D spheroids and in NOD/SCID mice xenografts leading to the eventual establishment of the CR4 human colorectal cancer cell line.
Majority of CR4 cells express high but variable levels of common cancer stem cell markers including CD44, CD166, EpCAM, and Lgr51. CR4 cell line has the G12V mutation on KRAS exon 2 (Botchkina GI, communications).

Reference:
1. Rowehl RA, Burke S, Bialkowska AB, Pettet DW III, Rowehl L, Li E, Antoniou E, Zhang Y, Bergamaschi R, Shroyer KR, Ojima I., Botchkina GI (2014) PLOS 9(6): e99091.

Colorectal cancer (CRC) is the 2nd highest cause of cancer death in the United States. Increasing evidence suggests that a small population of cancer-initiating cells (CICs) or cancer stem cells (CSCs) are responsible for tumorigenesis and the exceptional drug resistance to anti-cancer therapies.

Subject to local law, this product is intended to be sold for internal in vitro research use only subject to terms and conditions found here: www.sigmaaldrich.com/restrictedcelluse. This product may not be: re-engineered or copied; used to make derivatives, modifications or functional equivalents; used to obtain patents or other IP claiming use of the product; used to develop, test, or manufacturer a commercial product; used as a component in a commercial product; resold or licensed; used in any clinical applications or trials; or used in humans. A license or limited commercial use agreement is required for use by any for-profit entity, use in services, and use in sponsored academic research. For information regarding any such use, please contact licensing@milliporesigma.com.